Clinical trials: Patent
Dentatorubral-Pallidoluysian Atrophy
Personalized Antisense Oligonucleotide for A Single Participant With ATN1 Gene Mutation
This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with dentatorubral-pallidoluysian atrophy (DRPLA) due to a heterozygous pathogenic CAG trinucleotide…
- Trial name
- NCT07084311
- Testing
- nL-ATN1-002
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- n-Lorem Foundation
Congenital Heart Diseases
Ulinastatin Injection in in Pediatric Patients Undergoing Open Heart Surgery
1. Explore the efficacy of Ulinastatin use in improving post-operative pulmonary insufficiency and safety in pediatric patients undergoing scheduled CPB open heart surgery to treat Complex Congenital Heart Disease 2.
- Trial name
- NCT02527811
- Testing
- Ulinastatin
- Where
- 5 sites in China
- Volunteers
- 450 people
- Sponsor
- Techpool Bio-Pharma Co., Ltd.
Relapsed/Refractory Multiple Myeloma
Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma
The purpose of this study is to assess safety, efficacy, pharmacokinetic (PK)/pharmacodynamic (PD), and immunogenicity with ISB 1342 in subjects with relapsed/refractory multiple myeloma.
- Trial name
- NCT03309111
- Testing
- ISB 1342
- Where
- 20 sites in United States, France
- Volunteers
- 81 people
- Sponsor
- Ichnos Sciences SA
Open Abdomen
Post Market Clinical Follow Up Study of Avance Foam Abdominal Dressing Kit in Open Abdomen
The investigation is a Post Marketing Follow-Up Study for the Avance Foam Abdominal Dressing Kit conducted as part of Mölnlycke Health Care's quality system.
- Trial name
- NCT01968811
- Testing
- Avance Foam dressing kit
- Where
- Sweden
- Volunteers
- 10 people
- Sponsor
- Molnlycke Health Care AB
Epidermolysis Bullosa Dystrophica, Squamous Cell Carcinoma
Rigosertib for RDEB-SCC
Epidermolysis bullosa (EB) is a heritable skin disease characterized by marked fragility of epithelialized tissue with blistering in skin and mucous membranes following the slightest mechanical trauma.
- Trial name
- NCT03786237
- Testing
- Rigosertib Oral Capsules / Rigosertib Intravenous
- Where
- Austria
- Volunteers
- 2 people
- Sponsor
- Prof. Johann Bauer
Acute Heart Failure
Study to Evaluate the Effectiveness of High Dose Statin Loading in Acute Heart Failure Patients
This is a prospective, single-center, randomized, controlled, open-label, pilot study to evaluate the effectiveness of high dose statin loading in acute heart failure patients.
- Trial name
- NCT01127945
- Testing
- statin
- Where
- South Korea
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Asthma
Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study
Reslizumab is a type of medicine called a monoclonal antibody that is made in the research clinic; it works by blocking a specific protein in the body called interleukin-5.
- Trial name
- RITE (NCT02947945)
- Testing
- Reslizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Jewish Health
Pulmonary Arterial Hypertension
Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso
This was a Phase 1b safety and tolerability single-sequence study in which PAH subjects on a stable regimen of Tyvaso switched to a corresponding dose of TreT.
- Trial name
- BREEZE (NCT03950739)
- Testing
- Treprostinil Inhalation Powder
- Where
- 16 sites in United States
- Volunteers
- 51 people
- Sponsor
- United Therapeutics
Cerebral AV Malformation
PHIL Evaluation in the Endovascular Treatment of Intracranial Cerebral ArterioVenous Malformation (cAVM)
The primary objective of this study is to assess the efficacy and safety of PHIL® liquid embolic agent in endovascular embolization of cerebral arteriovenous malformations.
- Trial name
- NCT03341039
- Where
- 16 sites in Denmark, France and 3 more
- Volunteers
- 20 people
- Sponsor
- Microvention-Terumo, Inc.
Highly Sensitized Patients on Waiting List for Kidney Transplantation
Safety and Tolerability of Inebilizumab, VIB4920, or the Combination in Highly Sensitized Candidates Awaiting Kidney Transplantation From a Deceased Donor
Viela Bio is conducting an open-label, randomized study of inebilizumab, VIB4920, or the combination as part of a multi-center study in highly sensitized patients on the deceased donor waiting list for kidney transplantation.
- Trial name
- NCT04174677
- Testing
- Inebilizumab, VIB4920, Inebilzumab+VIB4920
- Where
- 2 sites in United States
- Sponsor
- Amgen
Breast Cancer, Non-small Cell Lung Carcinoma
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
This two-part study will include a dose escalation part to determine the recommended dose for expansion of DS8201a and pembrolizumab and a dose expansion part to evaluate efficacy, safety, and tolerability of the combination.
- Trial name
- NCT04042701
- Testing
- Trastuzumab deruxtecan (DS-8201a), Pembrolizumab
- Where
- 30 sites in United States, France and 2 more
- Volunteers
- 115 people
- Sponsor
- Daiichi Sankyo
Atrial Fibrillation
Safety Study of Tecadenoson to Treat Atrial Fibrillation
Assess the tolerability and safety of a rapid bolus of tecadenoson at different dose levels when given alone and in combination with a beta-blocker (esmolol) in patients with atrial fibrillation to control rapid heart rate.
- Trial name
- NCT00713401
- Testing
- Tecadenoson, Esmolol
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Gilead Sciences
Keratocystic Odontogenic Tumor
A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic Tumors
The purpose of this study is to determine how well a daily dose of 150 mg of Erivedge (vismodegib) reduces Keratocystic odontogenic tumor (KCOT) size, and to evaluate the safety of this dose.
- Trial name
- KCOT (NCT02366312)
- Testing
- vismodegib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- NYU College of Dentistry
Chondrosarcoma
A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g)
This is a multicenter, open-label, Phase II trial designed to evaluate the efficacy and safety of PRO95780 when given as a single agent in patients with advanced chondrosarcoma.
- Trial name
- NCT00543712
- Testing
- PRO95780
- Where
- 4 sites in United States, Australia
- Volunteers
- 15 people
- Sponsor
- Genentech, Inc.
Group B Strep Infection
Group B Streptococcus Response After Probiotic Exposure
This is an open-label randomized control trial and feasibility study designed to determine the feasibility of a larger RCT in our setting that would examine prenatal probiotic use in Group B Strep (GBS) positive pregnant women at…
- Trial name
- GRAPE (NCT04721912)
- Testing
- Probiotic dietary supplement
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of New Mexico
Metastatic Prostate Cancer
AI-Assisted Patient Support in mHSPC
The purpose of this multicenter, open-label, randomized controlled trial is to evaluate whether patient-centered support delivered through a large language model (LLM)-based artificial intelligence (AI) agent reduces anxiety in…
- Trial name
- LUMINOUS (NCT07804030)
- Testing
- The Same Platform without AI Agent, AI Agent-Assisted Patient-Centered Support, Delayed AI Agent-Assisted Patient-Centered Support
- Where
- 4 sites in China
- Volunteers
- 160 people
- Sponsor
- Fudan University
Ulcerative Colitis (UC)
Dose-Evaluation Study of the Efficacy and Safety of TLA Gut™ Leukapheresis Treatment in Patients With Ulcerative Colitis
An open-label, randomised, multi-centre, dose evaluation study of the efficacy and safety of TLA Gut™ leukapheresis treatment in patients with UC.
- Trial name
- NCT04550130
- Testing
- TLA Gut™
- Where
- Sweden
- Volunteers
- 12 people
- Sponsor
- TLA, Targeted Immunotherapies AB
Refractory Metastatic Colorectal Cancer, Solid Tumor
Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers
This Phase Ib/IIa study comprises a Main Study and a Study Extension. The Main Study has been designed according to a 3+3 Dose Escalation/dose Expansion design in refractory pMMR-MSS mCRC patients.
- Conditions
- Refractory Metastatic Colorectal Cancer, Solid Tumor, Metastatic Microsatellite-stable Colorectal Cancer, Mismatch Repair Protein Proficient
- Trial name
- NCT05205330
- Testing
- CR6086, AGEN2034
- Where
- 3 sites in Italy
- Volunteers
- 107 people
- Sponsor
- Rottapharm Biotech
Patent Ductus Arteriosus, Prematurity
Early Versus Late Use of Ibuprofen for Patent Ductus Arteriosus (PDA) Closure
The primary objective is to evaluate the Patent Ductus Arteriosus (PDA) closure rate of early vs. late use of Ibuprofen (Ibu). The investigators believe that early use of Ibu will have a higher PDA closure rate than later use of…
- Trial name
- NCT00833365
- Testing
- Ibuprofen
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Utah
Primary Sjögren's Syndrome
A Study of INCB050465 in Primary Sjögren's Syndrome
The purpose of this study is to assess the impact of parsaclisib on the signs and symptoms of Sjögren's syndrome (SS).
- Trial name
- NCT03627065
- Testing
- Parsaclisib
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Incyte Corporation